Welcome to our dedicated page for Royalty Pharma Plc SEC filings (Ticker: RPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
Royalty Pharma plc is asking shareholders to vote at its 2026 Annual General Meeting on June 4, 2026 in New York. Items include electing nine directors, advisory votes on U.S. and U.K. executive pay, auditor ratifications, authority to repurchase Class A shares, and approvals to allot shares with and without pre-emption rights.
The company highlights 2025 performance with $3.3BN in portfolio receipts, $3.0BN in adjusted EBITDA, $2.7BN in portfolio cash flow, and $4.7BN in announced transaction value. It returned over $1.7BN to shareholders, including more than $1.2BN of buybacks, while deploying $2.6BN into royalty acquisitions.
Royalty Pharma completed internalization of its external manager, emphasizing stronger board oversight of compensation and succession. The largely independent, skills-diverse board—led by Chairman and CEO Pablo Legorreta and Lead Independent Director Ted Love—stresses pay-for-performance, robust share ownership guidelines, risk oversight, and corporate responsibility initiatives around responsible investment, human capital, and sustainability.
Royalty Pharma plc EVP & CFO Terrance P. Coyne, through affiliated entities, reported planned open-market sales of Class A Ordinary Shares. On April 1, 2026, TPC RP EPA1 LLC sold 1,875 shares and TPC RP 2021, LLC sold 32,916 shares at a weighted average price of $48.3318 per share, all under a Rule 10b5-1 trading plan adopted on August 8, 2025. After these sales, TPC RP EPA1 LLC held 42,011 shares and TPC RP 2021, LLC held 32,916 shares. Additional holdings reported include 24,170 shares in a spouse’s IRA, 23,270 shares in an IRA, 1,500 shares held directly, and 1,450 shares held by a spouse, indicating that the transactions represent a partial reduction of a larger overall position.
TPC RP EPA1 LLC and TPC RP 2021 LLC reported multiple sales of Common Stock under Form 144. The filings list numerous dispositions between 01/02/2026 and 03/23/2026, including large line items such as 108,759 shares sold on 02/03/2026 and 69,665 shares sold on 02/02/2026. The entries show per-transaction share amounts and gross proceeds for each sale.
Bassler Bonnie L reported acquisition or exercise transactions in this Form 4 filing.
Royalty Pharma plc director Bonnie L. Bassler received an equity grant of 815 Class A Ordinary Shares. The award was made on a grant/award basis at a reference price of $45.977 per share and was issued under the company’s 2020 Independent Director Equity Incentive Plan in lieu of a $37,500 quarterly retainer payment. Following this grant, Bassler directly holds 73,947 Class A Ordinary Shares.
Royalty Pharma plc reported that entities associated with EVP & CFO Terrance P. Coyne sold Class A Ordinary Shares of the company. On March 23, 2026, TPC RP 2021, LLC sold 32,916 shares and TPC RP EPA1 LLC sold 1,875 shares in open-market transactions at a weighted average price of $45.5287 per share, with individual prices ranging from $45.30 to $45.94.
All reported transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025. After these sales, TPC RP 2021, LLC held 65,832 shares and TPC RP EPA1 LLC held 43,886 shares, and Coyne also reported additional indirect and direct holdings through various IRA and family accounts.
RPRX affiliates reported multiple Rule 144 sales of Common Stock. The excerpt lists numerous dispositions by two related holders, TPC RP EPA1 LLC and TPC RP 2021 LLC, across January–March 2026. Examples include sales of 1,875 and 32,916 shares by those entities, respectively.
Reporting persons filed Form 144 reporting proposed and completed sales of Common Stock of RPRX. The excerpt lists multiple transactions by related entities, including sales on 12/17/2025, 01/07/2026, and 03/18/2026, with individual trade sizes such as 79,346, 123,965, and 100,462 shares respectively. Examples shown include sales by GWL 2014 G LLC (79,346 shares on 12/17/2025) and George Lloyd IRA (136,980 shares on 03/04/2026). The filing records gross proceeds for each sale in U.S. dollars alongside the share counts.
RPRX submitted a Form 144 reporting a proposed sale of 100,462 shares of Common Stock acquired on 06/20/2020.
The filing lists the broker Goldman Sachs & Co. LLC and records multiple sales by affiliated entities over the prior three months, including transactions dated 01/07/2026, 01/21/2026, and 03/04/2026 with share amounts and gross proceeds documented in the filing.
Royalty Pharma plc executive vice president and CFO Terrance P. Coyne reported indirect open-market sales of a total of 34,791 Class A ordinary shares of Royalty Pharma plc on March 2, 2026. The sales were made by entities TPC RP 2021, LLC and TPC RP EPA1 LLC at weighted average prices around $46.67 and $47.01 per share, in multiple transactions within disclosed price ranges. All reported transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025.
Repare Therapeutics related entities reported multiple sales of common stock under a Form 144. The excerpt lists transactions by GWL 2013 NG LLC and GWL 2014 G LLC on several dates in December 2025 through February 2026.
Examples shown include 123,965 shares sold on 01/21/2026 and 110,000 shares sold on 12/03/2025. The filing records dollar proceeds for each sale in the excerpt.